Skip to main content

Table 2 Characteristics of subjects according to fasting glucose

From: Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor

Variable

Subjects with fasting glucose < 100 mg/dL (n = 76)

Subjects with fasting glucose ≥100 mg/dL and < 126 mg/dL (n = 19)

Subjects with T2DM (n = 11)

p

Sex (male: n, %)

41, 53.9

9, 47.4

5, 45.5

0.721

Cigarette (yes: n, %)

22, 28.9

4, 26.7

3, 30

0.663

CML (n, %)

59, 80.8

13, 72.2

10, 90.9

0.747

GIST (n, %)

14, 18.4

5, 27.8

1, 9.1

Age (years)

38.6 ± 15.7

41.8 ± 16.8

53 ± 14.2

0.023

Weight (kg)

70.5 ± 15.1

64.2 ± 14.4

65.3 ± 10.7

0.486

Weight (after 1 month, kg)

69.6 ± 14.9

63.7 ± 12.6

74.4 ± 27.5

0.645

Weight (after 6 months, kg)

74.9 ± 16.6

78.5 ± 10

61.6 ± 7.5

0.127

Mg (mg/dL)

2.2 ± 0.25

2 ± 0.20

2.1 ± 0.38

0.098

Mg (after 1 month, mg/dL)

2 ± 0.6

1.9 ± 0.18

2.25 ± 0.21

0.343

Creatinine (before, mg/dL)

0.90 (0.68–1)

1.02 (0.62–1.13)

1.02 (0.75–1.12)

0.260

Creatinine (after 1 month, mg/dL)

0.81 (0.70–0.90)

0.94 (0.68–1.05)

0.90 (0.60–1.10)

0.549

Creatinine (after 6 months, mg/dL)

0.86 (0.73–0.99)

0.84 (0.58–1.06)

0.84 (0.73–0.98)

0.239

ALT (before, U/L)

23.6 (14–26.5)

45.8 (14.2–48.2)

31 (17–48.5)

0.293

ALT (after 1 month, U/L)

24.9 (15–30)

51.3 (19–54.7)

17.8 (13–23.5)

0.008

ALT (after 6 months, U/L)

22.3 (17–26)

23.4 (20–27.5)

16. 5 (15.2–17.7)

0.106

  1. p value was obtained with Kruskal-Wallis or chi-square test
  2. CML chronic myeloid leukemia, GIST gastrointestinal stromal tumor, IFG impaired fasting glucose, Mg magnesium, ALT alanine aminotransferase